Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03575052 · ClinicalTrials.gov registry record · Phase 3
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
A Phase 3 study of Neuropsychiatric Symptoms Related to Neurodegenerative Disease, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 784
- Enrollment target
- 20
- Study locations
NCT03575052: Completed Phase 3 study of Neuropsychiatric Symptoms Related to Neurodegenerative Disease, sponsored by ACADIA Pharmaceuticals.
NCT03575052 is a Phase 3 study of Neuropsychiatric Symptoms Related to Neurodegenerative Disease that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 784 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03575052, a Phase 3 study of Neuropsychiatric Symptoms Related to Neurodegenerative Disease, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 784 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
Primary Outcome
Number (%) of patients with treatment-emergent AEs
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pimavanserin
Study Locations (20)
Florida
- Indago Research & Health Center Inc - Hialeah
- Reliable Clinical Research, LLC - Hialeah
- Axcess Medical Research - Loxahatchee Groves
- Premier Clinical Research Institute, Inc. - Miami
- Global Medical Institutes - Miami
- Future Care Solution, LLC - Miami
- MediClear Medical & Research Center, Inc. - Miami
- Novel Clinical Research LLC - Miami
- Laszlo J Mate, MD, PA - North Palm Beach
- University of South Florida - Tampa
- Synexus Clinical Research US - The Villages
California
- ATP Clinical Research, Inc. - Costa Mesa
- Syrentis Clinical Research - Santa Ana
Arizona
- Cognitive Clinical Trials - Gilbert
Massachusetts
- Boston Center Memory - Newton
Nebraska
- Cognitive Clinical Trials LLC - Papillion
New Jersey
- The NeuroCognitive Institute - Mount Arlington
North Carolina
- UNC Hospital - Chapel Hill
Ohio
- Insight Clinical Trials LLC - Shaker Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 784 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2022-05-06 |
| Phase | Phase 3 |
What the finished NCT03575052 record still lists
NCT03575052 is an interventional study that assigns participants to a tested intervention. The registered 784 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Neuropsychiatric Symptoms Related to Neurodegenerative Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03575052 names 20 study sites across 9 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03575052 about?
NCT03575052 is a clinical study titled "A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease". The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
What is the current status of trial NCT03575052?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 784 participants. The study started on 2018-05-21. Estimated completion is 2022-05-06.
What conditions does trial NCT03575052 study?
This clinical trial studies the following conditions: Neuropsychiatric Symptoms Related to Neurodegenerative Disease.
What interventions are being tested in trial NCT03575052?
The interventions under investigation include: Placebo (DRUG), Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT03575052?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03575052 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03575052's enrollment target sits among peer trials
784 433rd of 2000 higher than 1,568 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06118723 · 784 participants
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- NCT06498128 · 785 participants
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
- NCT06575192 · 783 participants · Phase 3
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
- NCT07276724 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI